Stay updated on Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page.

Latest updates to the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page revision tag was updated from v3.6.2 to v3.6.3, indicating a minor documentation/version update.SummaryDifference0.0%

- Check24 days agoChange DetectedRevision: v3.6.2 was added and v3.6.0 was removed. This indicates a page update or maintenance rather than any new or altered study details.SummaryDifference0.0%

- Check39 days agoChange DetectedNew help/navigation sections were added: How to Read a Study Record, Common Questions, and How to Join a Study. A recruitment status note indicates enrollment is closed ('No longer looking for participants'), and a site revision (Revision: v3.6.0) was added.SummaryDifference0.3%

- Check46 days agoChange DetectedRevision: v3.5.5 has been added to indicate the latest update to the page content. The previous revision, v3.5.4, has been removed.SummaryDifference0.0%

- Check67 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4 on the page, indicating a new release of the content. The change appears to be a minor, non-user-facing maintenance update and does not modify the study information or core functionality presented to users.SummaryDifference0.0%

- Check82 days agoChange DetectedThe page revision was updated from v3.5.2 to v3.5.3, representing a small update to the page metadata. No substantive study information appears to have changed.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page.